Olokizumab 64 mg
Sponsors
R-Pharm International, LLC, R-Pharm
Conditions
COVID-19
Phase 2
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
CompletedNCT04380519
Start: 2020-04-23End: 2020-07-24Updated: 2022-01-24
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).
WithdrawnNCT04452474
Start: 2020-06-30End: 2021-01-29Updated: 2021-11-08